113P Breast-cancer recurrence after completing adjuvant endocrine therapy at 5 years

Endocrine therapy (ET) for 5 years substantially reduces recurrence rates and increases survival in patients with estrogen-receptor (ER)–positive breast cancer. Recently, large-scale clinical data have shown further benefit of extended ET up to 10 instead stopping at years. We evaluated demographic factors associated late after 5-year completion ET. This retrospective analysis used medical records 1, 058 ER-positive cancer who underwent curative operation completed scheduled endocrine no two institutions between 2001 2014. assessed the associations clinical-pathological patients’ outcomes. The mean follow-up period was 13.2 (ranging from 5.6 23.3 years). All type rate 12.5% distant metastasis observed 69 (6.5%) related original TN status (p<0.001) kind regimen (tamoxifen (TMX) versus aromatase inhibitors, p=0.038). Distant recurrence-free showed statistically significant difference according stage tumor grade (p=0.017) Kaplan-Meier analysis. Tumor diameter over than 2cm axillary lymph nodes were significantly poor outcomes Cox regression analyses (tumor size HR 3.770, 95%CI:1.993-7.130, p<0.001 LN 2.105, 95%CI:1.201-3.691, p<0.001). After adjuvant ET, stages predicted relapse Risk reported herein may provide insights optimize decision making regarding